{"id":3259,"date":"2021-06-02T20:25:46","date_gmt":"2021-06-02T20:25:46","guid":{"rendered":"https:\/\/stuarttherapeutics.com\/?page_id=3259"},"modified":"2023-10-25T14:40:30","modified_gmt":"2023-10-25T14:40:30","slug":"technology","status":"publish","type":"page","link":"https:\/\/stuarttherapeutics.com\/technology\/","title":{"rendered":"Technology"},"content":{"rendered":"

Our Technology – PolyCol<\/i><\/b><\/span><\/h4>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div>
Stuart Therapeutics and PolyCol<\/em><\/strong><\/span><\/h5>\n

Stuart Therapeutics is developing a synthesized polypeptide therapeutic, (PolyCol<\/em><\/strong><\/span>), that targets and heals specific areas of collagen damage that are implicated in chronic diseases of the eye.\u00a0 In several chronic ophthalmic indications, disease processes release enzymes called matrix metalloproteinases (MMPs) that degrade and remodel collagen proteins. One specific area of degradation is in helical collagen structures (found in all collagen types).\u00a0 These helical structures are the home for important cell signaling proteins in healthy tissue.\u00a0 When degraded by MMPs, these helical structures cease hosting of signaling proteins, leading to inflammation and further damage.\u00a0 Normally, collagen is replaced quite slowly compared to cellular tissues.\u00a0 Healthy collagen structures are required for full and healthy recovery of the affected tissues.\u00a0 As people age, the body\u2019s ability to produce replacement collagen is reduced, thus leading to chronic disease.\u00a0 PolyCol<\/em><\/strong><\/span> is structured as a fractional single strand of amino acids that are mimics of sequences found in normal helical collagen.\u00a0 It is specifically designed to bind or intercalate into the key damage areas, restoring cell signaling and the structural role that collagen plays in healthy tissues.\u00a0 It works quickly, and results in the rapid restoration of tissue health and reduction in inflammation. PolyCol<\/em><\/strong><\/span> is being developed for several common disease indications in ophthalmology: Dry Eye Disease, Glaucoma, Dry Age-Related Macular Degeneration and Myopia.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/div>

Our lead product candidate, ST-100, is being developed for the signs and symptoms of dry eye disease (DED).\u00a0 Stuart\u2019s ST-100 is a targeted tissue reparative technology, restoring the helical collagen structures to their primary structural and cell signaling ligand binding site role.\u00a0 This results in an extremely robust recovery of corneal nerve function, and the ocular surface, including goblet cells and corneal epithelium.<\/p>\n

View Publications and References<\/a><\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div><\/div>
<\/div>
POLYCOL<\/span><\/h6>\n<\/div>

Our Science<\/span><\/h4>\n<\/div>

Stuart Therapeutics will begin its Phase 3 clinical trial for its first drug candidate, ST-100 (vezocolmitide) for Dry Eye Disease in December of 2023. The company has also completed extensive in vitro and in vivo research to profile the multiple amino acid sequence variants of the PolyCol<\/strong><\/em> platform, including their impact on accelerating tissue healing and reduction of inflammation in other important ophthalmic indications.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":4317,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false},"_links":{"self":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/3259"}],"collection":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/comments?post=3259"}],"version-history":[{"count":3,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/3259\/revisions"}],"predecessor-version":[{"id":4994,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/3259\/revisions\/4994"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media\/4317"}],"wp:attachment":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media?parent=3259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}